

TARO PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
September 14, 2006

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

**Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934**

September 14, 2006

Taro Pharmaceutical Industries Ltd.

(Exact name of registrant as specified in its charter)

14 Hakitor Street, Haifa Bay 26110, Israel

(Address of principal executive offices)

000-22286

(Commission File Number)

Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F:

Form 20-F / x / Form 40-F / /

Indicate by check mark whether the registrant by furnishing the
information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes / / No / x /

On September 13, 2006 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference

(c) Exhibit 99.1. Press release dated September 13, 2006

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Taro Pharmaceutical Industries Ltd.

(Registrant)

September 14, 2006

/s/ KEVIN CONNELLY

(Date)

Kevin Connelly
Senior Vice President and Chief Financial Officer